摘要
目的探讨胺碘酮治疗充血性心力衰竭并室性心律失常的疗效及安全性。方法将符合条件的160例充血性心力衰竭并室性心律失常患者随机分为治疗组及对照组,对照组给予常规抗心力衰竭加倍他乐克治疗,治疗组在常规治疗的基础上加胺碘酮治疗,对比分析两组患者在抗室性心律失常、左室射血分数、心脏性猝死、心力衰竭再住院率、药物不良反应等方面的情况。结果治疗组心功能改善和抗心律失常疗效优于对照组,再入院率和病死率低于对照组,差异有显著性(P<0.05),两组的不良反应无差异性(P>0.05)。结论胺碘酮治疗充血性心力衰竭合并室性心律失常安全、有效,不良反应轻。
Objective To explore the efficacy and safety of Amiodarone in patients with congestive heart failure and ventricular arrhythmias.Methods Totally 160 cases of eligible congestive heart failure and ventricular arrhythmias were randomly divided into treatment group and control group,control group received conventional anti-heart failure therapy plus metoprolol,the treatment group was treated on the basis of routine additional amine ketone iodine,compared two groups of anti-arrhythmia,left ventricular ejection fraction,sudden cardiac death,heart failure readmission rates,adverse drug reactions and other aspects.Results The improvement in heart function and anti-arrhythmic efficacy of treatment group better than the control group,the readmission rate and mortality rate lower than the control group,the difference was significant（P0.05）,the two groups was no difference in adverse events（P0.05）.Conclusion Amiodarone in patients with congestive heart failure with ventricular arrhythmias is safe and effective,less adverse reactions.
出处
《医药论坛杂志》
2010年第21期81-82,共2页
Journal of Medical Forum
